Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC)
Status:
Terminated
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this phase I study is to determine the maximal tolerable dose (MTD) of
thalidomide (THADO®) in combination with fixed dose of sorafenib (NEXAVAR®) for the treatment
of advanced or metastatic HCC.
The Phase II purpose of this study is to determine the disease control rate (complete
response + partial response + stable disease) for at least 4 months of sorafenib (NEXAVAR®)
plus phase I determined MTD of thalidomide (THADO®) in patients with advanced or metastatic
HCC.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
National Health Research Institutes, Taiwan
Collaborators:
Chang Gung Memorial Hospital National Cheng-Kung University Hospital